This company-commissioned publication (funded by Bayer) summarises data from a prospective cohort study which compared the risk of adverse renal outcomes associated with rivaroxaban or warfarin in patients with baseline preserved renal function and non-valvular atrial fibrillation. The study found reduced risk of renal decline and rate of renal decline in patients treated with rivaroxaban versus warfarin in UK primary practice settings.
Please login below to download this issue (PDF)